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The Journal of Craniofacial Surgery  Volume 00, Number 00, Month 2015Abstract: Human adipose-derived stem cells (hASCs) have been
proposed as a possible therapy for tissue regeneration in aesthetic,
plastic, and reconstructive surgery. Today, platelet concentrates are
used in a wide range of disciplines, but their storage has become a
controversial aspect. The purpose of this in vitro study was to
evaluate the effect of plasma rich in growth factors (PRGF), after
a freeze–thawing cycle, on the proliferation and biological activity of
progenitor cells involved in soft tissue healing. Different formulations
of activated PRGF were added to hASCs cultured in serum-free
medium. Cell proliferation was assessed by MTT test and cell count
up to 7 and 12-day incubation. Osteo-differentiation ability of hASCs
was also tested after 7 and 14-day incubation by alkaline phosphatase
assay. The effects of 4 PRGF preparations (fresh/frozen and with/
without platelets) were compared with corresponding formulations of
plasma poor in growth factors and with standard medium. hASCs
cultured in the presence of platelet concentrates increased prolifer-
ation rate with respect to cells grown in standard medium without
significant differences among all the tested plasma formulations on
cell viability up to 12 days of culture. PRGF activity is preserved after
cryopreservation and platelet-rich preparations promoted osteo-
differentiation of hASCs at day 7. In conclusion, PRGF supports
the proliferation and the differentiation of progenitor cells in vitro
also when applied after cryopreservation. Platelet concentrates, either
alone or in combination with mesenchymal stem cells, might be a
valuable tool in the field of tissue regeneration.
Key Words: Adipose-derived stem cells, osteogenic
differentiation, platelet concentrate, proliferation, tissue
regeneration
(J Craniofac Surg 2015;00: 00–00)A utologous fat grafting originally developed in 1983 for recon-structive purposes when Neuber applied the technique to the
treatment of facial defects, but over the last few decades, it has
become widely used in several areas of plastic and aesthetic
surgery.1 In craniofacial surgery adipose tissue transplantation is
applied to regeneration of peripheral facial nerve injures,2 to soft
tissue repair after irradiation of the maxillofacial area for neo-
plasms,3 and to the correction of peculiar facial deformities after
trauma.1 Furthermore, fat transplantation has been used in bony
reconstruction for the treatment of mandibular ameloblastoma
resection defects,4 the repair of large skull defects (ie, multifrag-
ment calvaria fracture),5 and the mandibular distraction osteogen-
esis.6 Autologous lipofilling has become popular in aesthetic and
plastic surgery for many indications, including scar remodeling
(especially in acne and burn patients), lip augmentation and deform-
ity treatment, mandibular and buccal deficiency of both bone and
soft tissue after tumor resection management, skin rejuvenation,
wrinkle filling, lipo-facelift, malar and mental regions augmenta-
tion,7 and breast reconstruction after cancer or for deformities.8 This
technique has found application also in vocal cord tissue regener-
ation,9 in the treatment of chronic ulceration,10 end-stage radiation
dermatitis,11 alopecia,12 and other medical applications.
Stem cell therapy has shown to be promising in aesthetic and
reconstructive surgery13 and several recent studies have shown
adipose tissue as a convenient source of multipotent adult stem
cells, called adipose-derived stem cells (ASCs). The first phase I–
III clinical trials were performed by Garcı´a-Olmo et al14 to inves-
tigate the efficacy and safety of expanded human adipose-derived
stem cells (hASCs) in the treatment of perianal fistulae including
Crohn disease. These mesenchymal stem cells possess the ability in
vitro to self-maintain and to differentiate toward cells of osteo-
genic,15 chondrogenic,16 adipogenic,15 myogenic,17 and neurogenic
lineage.18 In the last few decades the use of mesenchymal stem cells
in regenerative surgical procedures is steadily growing. Mesench-
ymal stem cells have been harvested since long from bone marrow
(BMSCs) for clinical use; however, in the last few years subcu-
taneous adipose tissue is being considered a convenient alternative
source since it contains a large number of progenitors and it can be
collected under local anesthesia with lower donor site morbidity.19
Several in vitro studies have shown the similarity between hASCs
and BMSCs regarding their cellular phenotype, growth kinetics, cell
senescence, and differentiation efficiency.20 On the basis of the
regenerative and immunomodulatory features of hASCs, they might
become useful tools for cell-mediated therapy.19 hASCs promote
tissue regeneration by secreting multiple cytokines and growth
factors, including insulin-like growth factor-1 (IGF-1), basic fibro-
blast growth factor (bFGF), hepatocyte growth factor, transforming
growth factor beta 1 (TGF-b1), platelet-derived growth factor
(PDGF), and the proangiogenic vascular endothelial growth factor,
that stimulate the recovery of damaged tissue in a paracrine1
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FIGURE 1. Overview of blood collection and different PC formulations
preparation. Citrate-anticoagulated whole blood was centrifuged to separate
blood cells into different layers, according to a density gradient. The bottom
fraction contained the red blood cells, while the upper acellular plasma part
contained platelets. The buffy coat layer of leukocytes separated acellular
plasma and erythrocytes (part I). The platelet-rich (PRGF) and platelet-poor
(PPGF) plasmas were collected and calcium chloride was added (part II).
Different plasma formulations were prepared activating for 30minutes at 378C
(immediately for fresh samples, after a freeze–thawing cycle for frozen ones) to
initiate the release of growth factors (green dashes) by the platelets (orange
spots). To remove the platelets, the clots were centrifuged and then the
supernatants were collected and used for cell culture (part III).
TABLE 1. Description of Plasma Preparations and Concentrations of the Most
Relevant Growth Factors
Growth Factors Concentrations
Sample
Platelet Count
MeanSD (103/mL)
PDGF-AB
(ng/mL)
TGF-b1
(ng/mL)
VEGF
(pg/mL)
Whole blood 248.14 31.13 – – –
PRGF 434.43 108.97 18.9 4.1 39.2 3.5 152.7 18
PPGF 415.71 111.17 1.37 0.06 87.6 11.69 361.1 119.5
PDGF-AB, platelet-derived growth factor AB; PPGF, plasma poor in growth
factors; PRGF, plasma rich in growth factors; SD, standard deviation; TGF-b1,
transforming growth factor beta 1; VEGF, vascular endothelial growth factor.
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stem cells to the site and the promotion of their differentiation
toward specific lineages. Due to these biological characteristics,
adipose tissue, previously discarded, has recently become an
invaluable stem cell source for clinical application.21 Platelet
concentrates (PCs) are regenerative preparations designed for the
local release of platelet growth factors into a surgical or wound site,
to stimulate tissue healing or regeneration. Consequently, autoge-
nous PCs have gained popularity as a medical treatment in a variety
of applications in different fields such as dentistry, oral surgery,
orthopaedics, sport medicine, dermatology, and plastic surgery,22
reducing also the patient’s postoperative discomfort. Pain, swelling,
and hematoma management is fundamental in any surgical pro-
cedure for preserving the patient’s postsurgery quality of life.23 The
rationale of using platelet concentrates is to release cytokines and
growth factors (GFs), stored in a-granules of platelets and released
upon activation. GFs are involved in the proliferation of connective
tissue progenitors, in the stimulation of fibroblasts and osteoblasts
activity, and in promoting angiogenesis, all processes essential for
tissue healing and regeneration.23
Plasma rich in growth factors (PRGF) is an autologous preparation
rich in platelets, easily and rapidly obtained from a small volume of
patient’s blood, which, being autologous, does not promote any
immune reaction nor may cause new infectious disease.24 In the
PRGF the leukocytes are excluded so as to avoid any proinflamma-
tory effects mediated by such cells.25 Therefore, patients’ own plasma
has been proposed as a carrier matrix for autologous growth factors
where the clinical conditions require tissue repair.
Since for surgical procedures requiring multiple treatments with
platelet concentrates, blood harvesting for each application is
needed, PC storage has become a controversial topic. Freeze–
thawing cycles allow an easier patient management and, in addition,
frozen samples are easy to handle and consequently useful for in
vitro validation of the sample functionality. On the other hand, they
are supposed to reduce platelet function and GFs release and
therefore may negatively affect the platelet concentrate’s biological
activity.26
The aim of this study was to assess the in vitro effect of PRGF
after a freeze–thawing cycle, on progenitor cells involved in soft
tissue regeneration, using PRGF as substitute for fetal bovine serum
(FBS). In particular, vitality, cell growth, and osteo-differentiation
of hASCs were evaluated. Additionally, the same experiments were
repeated using plasma poor in growth factors (PPGF) to assess if the
observed effects were due to plasmatic factors or to factors released
by platelets.
METHODS
Blood Collection and PC Preparation
The acellular plasma of a PC was obtained using a manual
protocol performed by an experienced technician. Peripheral blood
from 4 young healthy volunteer donors (3 women and 1 man, age
23–29 years (26.2 2.6)) was collected in 9-mL tubes (BTI blood
collecting tubes) with 3.8% sodium citrate (m/v) as anticoagulant.
PC was obtained by blood centrifugation at 580 grams for 8 min-
utes. Blood cells stratified according to a density gradient: the
bottom fraction contained erythrocytes and the top fraction con-
tained platelets. The 2 fractions were separated by the whitish buffy
coat layer, which contained most of the leukocytes. The 2 mL
plasma fraction just above the buffy coat, containing the highest
platelets concentration, was identified as plasma rich in growth
factors (PRGF) and collected. The plasma fraction above the PRGF
layer, presenting the lowest platelets concentration, was identified
as PPGF and also collected (Fig. 1).2Platelets count was obtained by a hematology analyzer (Sysmex,
XE-2100, Norderstedt, Germany). The quantification of growth
factors was performed by ELISA kits (R&D Systems, Minneapolis,
MI) and PDGF-AB, TGF-b1, and vascular endothelial growth
factor concentrations were determined following the manufac-
turer’s recommendations. These GFs were chosen for analysis
for their specific role in tissue healing and regeneration (Table 1).27
Different Plasma Formulations Preparation
After PRGF and PPGF fractions activation with CaCl2 solution
(PRGF-Activator, BTI Biotechnology Institute, Vitoria, Spain)
(Fig. 1, part II), different steps were performed to obtain 4 different
PRGF preparations: fresh PRGF with platelets (PRGFþ); frozen
PRGF with platelets (fPRGFþ); fresh PRGF without platelets
(PRGF), and frozen PRGF without platelets (fPRGF). fPRGFþ
was immediately aliquoted and stored at 808C until its use. After
being thawed in a water bath at 378C for a few minutes, it was# 2015 Mutaz B. Habal, MD
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vation and growth factors release and then used as supplement to the
culture medium. The other formulations were incubated at 378C for
30 minutes and PRGFþ was immediately added to the culture
medium, whereas PRGF was collected after centrifugation at
3000 g for 15 minutes at 48C to remove platelets. Finally, aliquots
of fPRGF were stored at 808C until testing, but not longer than
24 hours, while PRGF was immediately used.
Similarly, 4 PPGF plasma preparations were obtained from the
upper plasma fraction: fresh PPGF with platelets (PPGFþ); frozen
PPGF with platelets (fPPGFþ); fresh PPGF without platelets
(PPGF), and frozen PPGF without platelets (fPPGF). All PRGFs
and PPGFs formulations from each donor were individually tested
on human adipose-derived stem cells (Fig. 1, part III).
Cell Culture
Cells used in this study derived from plastic surgery discarded
tissues of healthy donors after their written consent and Institutional
Review Board approval (IRCCS Galeazzi Orthopaedic Institute PQ
7.5.125, version 3, 14.05.2012).
Human adipose-derived stem cells (hASCs) were isolated by
liposuction of 15 to 40 mL (28.3 12.6 mL) subcutaneous-adipose
tissue of 3 female patients (age 22–35 years (mean 29 6.5 years),
BMI< 30). After digestion with 0.075% type I collagenase
(Worthington, Lakewood, NJ) the stromal vascular fraction was
separated by centrifugation (1200 grams for 10 minutes), filtered
and hASCs were plated (100,000 cells/cm2) in basal medium
(DMEM) supplemented with 10% fetal bovine serum, 50 U/mL
penicillin, 50 mg/mL streptomycin and 2 mM L-glutamine. Cells
were maintained in a humidified atmosphere at 378C with 5% CO2
until confluence. Plastic culture flasks-adherent hASCs were
selected during subsequent passages. The fibroblast-like
morphology displayed by the isolated cells was checked by
phase-contrast microscopy and the doubling time was calculated
as (t2  t1) ln2/ln(N/N0), where N is the number of counted cells
and N0 represents the number of plated ones. Cell viability was
tested by means of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide (MTT) test, whereas the colony-forming unit-
fibroblast (CFU-F) frequency was established by counting individ-
ual colonies (of at least 20 cells) compared with the number of
seeded cells. hASCs were characterized immunophenotypically by
FACS Calibur flow cytometer (BD Biosciences Europe, Erembo-
degem, Belgium) as described previously.27 Cells were CD73,
CD90, CD105, and CD271 positive and CD14 and CD45 negative.
Multilineage differentiation potential into adipogenic, osteogenic,
and chondrogenic differentiation was confirmed (data not shown).
The hASCs purified yield after 25 days was 4.4 108 2.6 108.
Viability and Proliferation
MTT assay: Passage 3 to 5 cells were plated at a density of
1.5 104 cells/cm2 in 96-well tissue-culture plates. 2.5%, 5%
PRGF or PPGF, or 10% FBS (CTRL) were added to the cell culture
medium after 24 hours of culture in serum-free medium, to allow
cell cycle synchronization. After 1 and 7 days in culture, 0.5 mg/mL
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) was added and incubated for 4 hours at 378C. The formazan
precipitate was solubilized with 100% dimethylsulphoxide and the
absorbance read at 550 nm with a Celbio plate reader.
Cell count: From passage 1 to 3 in culture, cells were trypsinized
and plated at a density of 8 103 cells/cm2 in 6-well tissue-culture
plates in control medium. After 24-hour starvation, culture medium
was replaced by serum-free medium supplemented with either 2.5%
or 5% of PRGF or PPGF formulations or 10% FBS. At days 4, 8, 12,
cells were detached with 0.5% trypsin/0.2% EDTA and counted in a# 2015 Mutaz B. Habal, MDBurker chamber considering also trypan blue exclusion. All the
experiments were performed in duplicates.
Osteogenic Differentiation
From passage 1 to 3, hASCs were plated in 24-well tissue-
culture plates at a density of 7.5 103 cells/cm2 (day 7) and
5 103 cells/cm2 (day 14) and let adhere overnight in control
medium. After being washed and cultured for 24 hours in serum-
free medium either 2.5% PRGFþ or fPRGFþ or 10% FBS (CTRL)
were added. Osteogenic differentiation was induced under appro-
priate culture conditions (medium supplemented with 10 nM dexa-
methasone, 10 mM glycerol-2-phosphate, 150mM L-ascorbic acid-
2-phosphate, and 10 nM cholecalciferol) (OSTEO).
Alkaline phosphatase (ALP) assay-enzymatic activity was
measured at days 7 and 14. Cells were lysed with 0.1% Triton
X-100 and 1 mM p-nitrophenylphosphate in alkaline buffer
(100 mM diethanolamine and 0.5 mM MgCl2, pH 10.5) was added
to the cell lysate and incubated at 378C. The reaction was stopped
with 1N NaOH and absorbance read at 405 nm with a Wallac Victor
II plate reader. ALP activity was then normalized with respect to
each sample protein concentration determined by BCA protein
assay (Pierce Biotechnology, Rockford, IL).
Reagents, when not otherwise indicated, were provided by
Sigma-Aldrich, Milan, Italy.
Statistical Analysis
Data are expressed as meansSE and statistical analysis (one-
way analysis of variance) was performed by using GraphPad Prism
5.03 (GraphPad Software, San Diego, CA). Differences were
considered significant at P< 0.05.
RESULTS
Cell Proliferation and Viability
A preliminary dose study for choosing the ideal PC concen-
tration was performed. hASCs were incubated for 4, 8, 12 days in
medium enriched with 10% FBS (CTRL) or with 2.5% or 5% of
each of the plasma formulations. The percentage of increase or
decrease of cell number derived from 2 independent experiments
performed with PCs from 1 donor was calculated (Table 2). The
highest cell count values were obtained when hASCs were cultured
in media supplemented with 5% of any PC preparations, both in the
presence (Table 2A) and in the absence (Table 2B) of platelets.
After 12 days cells showed an increased proliferation up to 19.8-
fold for PRGF and to 21-fold for PPGF with respect to the control.
2.5% PC formulations induced a lower but comparable to the
control cell proliferation. Consequently, the remaining assays were
performed with 5% platelet concentrate as substitute for FBS.
At day 1, in all the fPRGFþ, PRGFþ, fPPGFþ, and PPGFþ
groups hASC viability was reduced compared with the control,
suggesting that hASCs required more time to adapt to the new
microenvironment. At day 7, hASC viability increased irrespec-
tively of the supplements added, and no difference was observed
anymore (Fig. 2A). A similar trend was observed by cell counting.
In all GFs-enriched media, hASCs proliferated faster than in CTRL
medium, confirming that these progenitors adapted easily to the
human supplements. In all the tested groups, the number of hASCs
collected after 12 days was about 10 times higher than the control.
fPRGFþ and fPPGFþ groups showed higher proliferation values
than the PRGFþ and PPGFþ, although this difference was not
statistically significant. In addition, no differences in cell prolifer-
ation were observed between the PRGFþ and PPGFþ fractions
(Fig. 2B).3
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FIGURE 2. Effect of plasma rich in growth factors (PRGF) and plasma poor in
growth factors (PPGF) on human adipose-derived stem cell (hASC) viability and
proliferation. Evaluation of cell viability with 5% fresh and frozen (f) PRGF, PPGF
in the presence (þ) (A) and in the absence () (C) of platelets. Data are shown as
means SE of 3 independent experiments performed with platelets
concentrates derived from blood of 3 donors. P<0.001 treated versus
control value. hASC proliferation with 5% fresh and frozen (f) PRGF, PPGF with
(B) and without (D) platelets. Data are shown as themeans SE (standard error)
of 3 independent experiments. At day 4 in the absence of plateletsP<0.001 fPRGF versus CTRL (control); ##P <0.01 fPRGF versus PRGF;
888P<0.001 fPRGF versus PPGF; §§P<0.01 fPRGF versus fPPGF. At day 8 in
the absence of platelets P <0.05 fPRGF versus CTRL (control); 8P<0.05
fPRGF versus PPGF (D). Higher magnification of statistically significant
difference in cell proliferation at day 4 (inset). Representative phase contrast
photomicrographs illustrating the proliferation rate of hASCs grown on a tissue
culture plate for 4 days in standard condition (CTRL) and in media
supplemented with PRGFþ, PRGF, PPGFþ, PPGF (40 magnification) (E).
TABLE 2. Effect of Different Concentrations of PCs on Human Adipose-Derived
Stem Cells Proliferation, Expressed as Percentage as Compared With Baseline
4 days 8 days 12 days
A PC (%) 2.5 5 2.5 5 2.5 5
With platelets PRGF 113 173 9 600 24 1323
fPRGF 110 336 15 1138 78 2364
PPGF 28 278 43 465 70 1092
fPPGF 18 214 50 1273 83 2511
4 days 8 days 12 days
B PC (%) 2.5 5 2.5 5 2.5 5
Without platelets PRGF 32 37 12 51 27 84
fPRGF 65 167 29 389 77 1915
PPGF 37 29 48 56 74 41
fPPGF 25 11 56 52 45 119
fPPGF, frozen plasma poor in growth factors; fPRGF, frozen plasma rich in growth
factors; PC, platelet concentrate; PPGF, plasma poor in growth factors; PRGF, plasma
rich in growth factors.
Ceci et al The Journal of Craniofacial Surgery  Volume 00, Number 00, Month 2015fPRGF, PRGF, fPPGF, and PPGF did not affect hASC
viability despite a large variability among samples (Fig. 2C). On the
other hand, hASC proliferation increased only with fPRGF,
PRGF, and fPPGF, whereas PPGF displayed similar results
as 10% FBS (Fig. 2D). At day 4, the presence of platelets seemed to
have a higher cell proliferation-inducing effect, in particular after
treatment with 5% PCs, than that observed in their absence (Fig. 2B
and D).
This result was also confirmed by phase contrast microscopy
that revealed a higher number of hASCs and the typical elongated
fibroblastic appearance when cells were grown in the presence of
any plasma formulations with respect to the control condition
(Fig. 2E).
The effect of fPRGFþ from several donors and on different
hASC populations was also analyzed. The interdonor variability
among platelet concentrates and hASC populations was less pro-
nounced at early time points compared with later ones, and the
marked effect of fPRGFþ, independently of its donor and of the
responder cells (different hASCs populations), was confirmed at a
later time point (Fig. 3).
Osteogenic Differentiation
ALP activity was determined in 2 hASC populations (ASC-I and
ASC-II) osteo-differentiated for 7 and 14 days in the presence of
either 2.5% PRGFþ or fPRGFþ. After 7 days ALP activity con-
siderably increased when platelet concentrates were present
(Fig. 4A). Cells cultured with both PRGFþ and fPRGFþ exhibited
higher levels of this marker compared with those cultured with FBS.
In addition, in the absence of osteo-differentiative stimuli ALP
activity was also induced. At day 14, the effect was reduced with
respect to day 7, but still present (Fig. 4B). In parallel, calcium
deposition tested by alizarin red staining (ARS) was also increased
after 14 days of differentiation by the presence of both PRGFþ and
fPRGFþ (data not shown).
DISCUSSION
The use of autologous platelet concentrate has spread in different
medical conditions for regenerative purpose.25 Its effects on tissue4regeneration have been shown in dentistry, oral implantology,
orthopaedics, sports medicine, and treatment of skin disorders.25
Currently, different techniques to obtain platelet concentrates are
available, but each method may lead to preparations that may differ
in platelet concentration, leukocyte, and fibrin content.28 PRGF is a
modified pure platelet-rich plasma, introduced by Anitua in 1999.24
The main difference with platelet-rich plasma is that according to
the Anitua’s protocol, leukocytes are intentionally excluded to
avoid proinflammatory effects of proteases and acid hydrolases
contained in white blood cells.25 In this study, we demonstrated
that PRGF preserves the ability of inducing in vitro proliferation
and osteogenic differentiation of hASCs, even after freeze–
thawing cycle.
The effect of PRGF was compared to control culture condition to
test if PRGF could be a possible alternative to FBS supplement in
cell culture media.
To date, little is known about the in vitro effect of platelet
concentrates on cell function. Despite the low number of studies
that investigated the effect of platelet concentrates on hASCs, the
effectiveness of PCs in combination with hASCs on cell stimulation
and tissue healing has been reported.3 This was also confirmed in
our study in which FBS was completely substituted by PC. In this# 2015 Mutaz B. Habal, MD
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FIGURE 3. (A, B) Effect of 5% frozen plasma rich in growth factors with platelets
(fPRGFþ) from different donors and (C, D) on different human adipose-derived
stem cells (hASC) populations. (A) Cell viability (MTTassay) and (B) proliferation
(cell count) of a single hASC population (I) cultured with 3 fPRGFþ samples (D1,
D2, D3). (C) Viability and (D) proliferation of 3 hASC populations (I, II, III)
cultured with a fPRGFþ sample. A representative experiment for each condition
is shown.
The Journal of Craniofacial Surgery  Volume 00, Number 00, Month 2015 Does Freeze–Thawing Influence PCsstudy, mesenchymal stem cells and platelet concentrate were not
harvested from the same donors. This choice was supported by a
previous study that reported that hASCs grown in the presence of
both human autologous and heterologous sera increased their
proliferation rate compared with standard culture condition,29
and especially with the absence of leukocytes from PRGF with a
consequent reduced risk of immune reaction between the PC cells
and the cultured ones. Although culture media have been supple-
mented with a lower concentration of plasma formulations com-
pared with other studies,30 after a short adaptation period, cell
viability and proliferation were comparable to the control ones in all
the tested groups. Interestingly, we observed similar effects
mediated by PRGF and PPGF (both fresh and frozen). One possible
explanation of this result could be the non-direct-correlation
between platelet count and growth factors concentration and the
unclear relationship between platelet count and cellular response, as
reported by Zimmermann et al31 and Eppley et al.22 On the other
hand, other authors reported that platelet count positively correlates
with the quantity of growth factors released.32 Due to the high
number of GFs contained in a-granules, it is very difficult, though it
could be relevant, to measure the levels of each of them. In
principle, several factors should be considered that may affect
the establishment of precise correlations. For example, the content
of GFs stored in, and the amount of GFs released by each cell, mayFIGURE 4. ALP activity of 2 human adipose-derived stem cell (hASC)
populations (I, II) osteo-induced in the presence of 2.5% of frozen plasma
rich in growth factors with platelets (fPRGFþ) and fresh plasma rich in growth
factors with platelets (PRGFþ) for 7 (A) and 14 (B) days. ALP activity is expressed
as U/mg proteins. A single experiment for each condition is shown. ALP, alkaline
phosphatise.
# 2015 Mutaz B. Habal, MDvary. We should keep in mind that platelets derive from fragmenta-
tion of larger cells, the megakaryocites, and this process does not
always generate identical cells. Furthermore, platelets activation,
which causes discharge of platelets granules content by exocytosis
in the extracellular space, may not occur in the same way and
simultaneously for all the platelets involved, especially in the in
vivo situation. The GFs’ release kinetics may vary according to the
interaction of platelets with the surrounding extracellular matrix
and/or with other cells and biological mediators involved in early
healing events.33
The possibility of storing platelet concentrates and the effects of
freeze–thawing cycles on platelet activity are poorly understood
and still under debate. Some researchers consider freeze–thawing a
procedure that could impair platelet function and lifespan, alter the
GFs’ release pattern, promote the pyrogenic cytokines accumu-
lation, and increase the risk of bacterial proliferation,26 whereas
other authors believe that it does not affect the platelet concentrate’s
final properties.34
In this study, we demonstrated that cryopreservation can be
regarded as a safe procedure to store platelet concentrates because
both fresh and frozen samples showed similar biological activities.
Despite Zimmermann et al35 reporting that freezing and thawing
damaged platelet membranes, causing extensive degranulation and
increase of GFs content in plasma, Perut et al36 showed that this
procedure reduced platelet number but did not affect the GFs
release. This result was also confirmed by Roffi et al37 whose
study underlined that although freezing and thawing affected the
GFs’ release kinetics, fresh and frozen PCs did not significantly
differ in their ability to induce cell proliferation. This storage option
could simplify the management of patients undergoing multiple
PCs application sessions, keeping however in mind that biological
results cannot always be directly translated into clinical outcomes.37
Although the aim of this study was just to compare the effect of
fresh and frozen platelet concentrates, as freezing could be con-
sidered a sample storage option, another interesting issue is the
possibility that a prolonged storage time could have a strong
influence on the results of platelet concentrates interactions with
hASCs. Currently, there is a lack of data available about the
preservation of biological activity potency of PCs after different
storage times, but Anitua et al38 demonstrated that PRGF eye drops
stored at 208C for 15, 30, and 90 days maintained the same
concentrations of the main proteins and growth factors and did not
affect the in vitro effects of the eye drops; therefore, this point will
be of great interest for future investigations.
In the present study, PCs were activated with calcium chloride
before freezing to induce releasing of the growth factors. Hence,
freezing was used only as a GFs storage method and not to produce
the so-called ‘‘platelet lysates’’; in fact, the latter derived by
mechanical disruption of platelet concentrates via freeze–thawing
cycles with no chemical activation.39 To assure the clinician on the
effectiveness of a regenerative treatment, it would be useful to
analyze the bioactivity of the patient’s own platelet concentrate, as
the GFs levels might vary among donors, with variable effects on
tissue healing. We believe that combining in vitro tests with the
clinical application might either encourage or save from using
autologous platelet concentrates in selected patients. Despite plate-
let count and PC growth factors content being likely influenced by
the donor’s age, sex, and thrombocyte count, Weibrich et al40 did
not find substantial variation in individual growth factors content
and the donor’s biological condition. In fact, our results indicated an
improvement of the biological analyzed parameters despite a mild
interdonor variability of the tested PCs.
To try to elucidate the PRGF potential in bone regeneration, its
pro-osteogenic activity was evaluated by ALP activity, an early
marker of osteogenic differentiation. Cells were maintained in5
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that even such low amount of PC was adequate to induce cell
proliferation. ALP activity assay showed that 2.5% PRGF, both
fresh and frozen, is capable of supporting in vitro differentiation of
hASCs suggesting that platelet concentrates contain per se osteo-
inductive factors that might activate some early steps of the osteo-
differentiative process of mesenchymal cells. Our results are con-
sistent with previous findings that demonstrated that the adjunct of
platelet concentrates to culture medium promotes the differentiation
of various cell types.36,41
In this study, we did not analyze platelet concentrates from
elderly donors, which hypothetically could show some variability
with respect to the plasma formulations from young volunteers.
This point should be further investigated in subsequent studies. All
types of PRGFs enhanced the cell proliferative and differentiative
capacity in vitro suggesting also that the concentrated cocktail of
bioactive components present in platelet concentrates could be a
valid substitute of FBS as supplement for culture medium as also
demonstrated by Creeper et al.41 Further studies will focus on the
proteomic analysis of the plasma concentrates with the idea to
deplete some factors involved in the healing process, to determine
their specific biological role.
In some instances, the results obtained here might suggest that
the presence of platelets is not always quite important, which is
misleading. We must take into account that the in vitro situation is
only partially comparable to the in vivo condition. In fact, the
biological environment of a healing tissue is extremely more
complex and undergoes continuous modifications regarding cell
composition, tissue pH, oxygen content. Moreover, in vivo, a far
greater number of signaling molecules are involved and may
interact with platelets and other cells in orchestrating the healing
process. Recent proteomics studies showed that more than 4000
soluble factors are contained into and released by the platelet
granules and for most of them the actual role is still unknown.42
Additional studies are needed to shed light on the actual role of
platelets in the tissue regeneration process.
In conclusion, this study demonstrated that cryopreservation
does not affect PC stimulating effect on cell proliferation and
differentiation and that hASCs might be an ideal tool for assessing
the activity of platelet concentrates. Consequently, we provide
evidence to support platelet concentrates in association with hASCs
as an attractive adjunct for reconstructive and aesthetic surgery.
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